JPMorgan raised the firm’s price target on PTC Therapeutics (PTCT) to $80 from $68 and keeps an Overweight rating on the shares following the Q3 report. The firm says PTC’s momentum in October “continued to look very favorable and sustained.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $93 from $73 at Wells Fargo
- PTC Therapeutics price target raised to $68 from $46 at Barclays
- PTC Therapeutics price target raised to $75 from $50 at Citi
- PTC Therapeutics: Strong Market Position and Growth Potential Drive Buy Rating
- PTC Therapeutics: Balancing Sephience Success with DMD Challenges and Strategic Shifts